Sermorelin vs MK-677
Side-by-Side Comparison
| Attribute | Sermorelin | Mk 677 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. | MK-677 binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, mimicking the hunger hormone ghrelin. |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase I–II Clinical Trials |
| Clinical Status | Previously FDA-approved (Geref, discontinued); now used off-label via compounding | Multiple Phase II trials completed. Not FDA-approved. Investigational. |
| Safety Profile | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) | Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain; Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics |
| Route | Subcutaneous | Oral (capsule or liquid) |
| Dose Range | 100–300 mcg/day SC | 10–25 mg/day orally |
| Frequency | Once daily (typically before bed) | Once daily |
| Molecular Weight | ~3357.9 g/mol | ~528.7 g/mol (624.8 as mesylate salt) |
| Half-Life | ~10–20 minutes | ~4–6 hours (plasma); functional activity ~24 hours |
Overview
Sermorelin and MK-677 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
MK-677 — Mechanism & Evidence
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections. Unlike injectable GH peptides such as GHRP-6 or Ipamorelin, MK-677 can be taken orally and maintains elevated GH and IGF-1 levels for up to 24 hours. It has been studied in several human clinical trials for GH deficiency, muscle wasting, bone density, and sleep quality, but is not FDA-approved for any indication.
Key claims: Increases growth hormone and IGF-1 levels; Improves sleep quality; Increases lean body mass.
Shared Research Applications
Both peptides are studied for: Anti-Aging, Body Composition, Sleep.
Sermorelin is also researched for: no additional unique applications.
MK-677 is also researched for: no additional unique applications.
Safety Considerations
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
MK-677: Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics Fatigue and lethargy reported by some users
Related Products
Sermorelin 5mg
5mg
Related Research News
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
Synergistic Growth Hormone Effects of Sermorelin and Ipamorelin Blend
Research peptides Sermorelin and Ipamorelin may work together to boost growth hormone release from pituitary cells through distinct pathways. Sermorelin mimics the active part of natural GHRH, while Ipamorelin targets GHS-R1a receptors selectively. Laboratory studies indicate this combination could produce higher hGH peaks than either alone, with potential anabolic benefits via IGF-1.